Midwest Biomedical Accelerator Consortium: MBArC

项目摘要/摘要 生物医学研究的最终目标是创造新的设备、药物和技术 预防、诊断和治疗人类疾病。就像科学发现一样，生物医学技术 商业化是复杂的，需要指导、资源、协作和风险。 然而，有几个障碍限制了有希望的实验室发现的商业化，包括 1)院士们缺乏商业化是一种选择的意识，2)担心 商业化的努力延缓了学术进步，以及3)未能将调查人员联系起来 以及完成商业化进程所需的合作者和专家。这个 本研究评估和商业化枢纽(REACH)提案的目标是 在密苏里哥伦比亚大学(MU)和密苏里大学之间建立合作伙伴关系 堪萨斯医学中心(KUMC)将促进学术创业和 商业化。在这次合作中，墨尔本大学带来了其杰出的生物医学和生物工程 参与库尔特翻译的研究项目及其充满活力的记录 研究伙伴奖计划。KUMC提供其卓越的生物医学研究 美国国立卫生研究院临床与转化科学奖(CTSA)。此外, 每个机构都有现有的合作伙伴关系，以加强和扩大联盟-即1)MU与 密苏里大学位于堪萨斯城、圣路易斯和罗拉的州立系统大学；以及2)KUMC 与堪萨斯IDEA卓越生物医学研究网络(K-INBRE)和可持续 中心地带加速器区域伙伴关系枢纽(SHARPHub)。这件事的领导班子 名为中西部生物医学加速器联盟(MBARC)的网络将采用 促进生物医学研究商业化的以下战略：1)利用MBARC的 地理和机构范围，以发展战略伙伴关系，邀请科学家 从事技术转让和商业化；2)对院士进行培训和 验证其创新的临床和商业可行性所需的资源，3)提供 有资金和指导的研究人员完成产品定义研究并吸引关注- 在资金方面，以及4)在生物医学创新和 企业家精神。这一倡议将建立在优秀机构现有计划的基础上，以 增加与健康相关的商业发展，包括在密苏里州、堪萨斯州、 以及毗邻的州。MBARC REACH中心将促进新科学的商业化 并建立可持续的基础设施，将科学发现转化为 预防和治疗困扰美国人口的高负担疾病的商业产品。

Project Summary/Abstract The ultimate goal of biomedical research is to create new devices, drugs, and technologies that prevent, diagnose, and treat human diseases. Like scientific discovery, biomedical technology commercialization is complex and requires mentorship, resources, collaboration, and risk. However, several hurdles limit commercialization of promising laboratory discoveries, including 1) lack of awareness by academicians that commercialization is an option, 2) concerns that commercialization efforts delay academic advancement, and 3) failure to connect investigators with the collaborators and experts necessary to complete the commercialization process. The objective of this Research Evaluation and Commercialization Hub (REACH) proposal is to establish a partnership between the University of Missouri-Columbia (MU) and the University of Kansas Medical Center (KUMC) that will promote academic entrepreneurship and commercialization. To this collaboration MU brings its outstanding biomedical and bioengineering research programs and its vibrant track record of participation in the Coulter Translational Research Partnership Award program. KUMC provides its exceptional biomedical research programs and Frontiers, its NIH Clinical and Translational Science Award (CTSA). In addition, each institution has existing partnerships that strengthen and extend the alliance - i.e. 1) MU with University of Missouri state system universities in Kansas City, St. Louis, and Rolla; and 2) KUMC with the Kansas Idea Network of Biomedical Research Excellence (K-INBRE) and the Sustainable Heartland Accelerator Regional Partnership Hub (SHARPhub). The leadership team of this network, entitled the Midwest Biomedical Accelerator Consortium (MBArC), will employ the following strategies to increase biomedical research commercialization: 1) leverage MBArC’s geographic and institutional scope to develop strategic partnerships that invite scientists to engage in technology transfer and commercialization, 2) give academicians the training and resources needed to validate the clinical and commercial feasibility of their innovations, 3) provide researchers with funding and mentorship to complete product definition studies and attract follow- on funding, and 4) offer experiential learning opportunities in biomedical innovation and entrepreneurship. This initiative will build on existing programs in outstanding institutions to increase health-related business development, including small businesses, in Missouri, Kansas, and adjoining states. The MBArC REACH Hub will promote commercialization of novel scientific discoveries and establish a sustainable infrastructure to translate scientific discoveries into commercial products that prevent and treat high-burden diseases afflicting the US population.